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Abstract
Background: Rapid diagnostic tests (RDTs) have been commercialized in order to help physicians in dengue
diagnosis. Until recently, only blood samples were used for those tests but it has been shown in several studies that
urine and saliva can also be employed for dengue diagnosis. RDTs for the detection of NS1 antigen and
anti-dengue IgG, IgM and IgA in urine and saliva specimens have thus been developed by Standard Diagnostics.
The aim of this study was to evaluate the performances these new commercial assays.
Methods: Two panels of clinical specimens were used: one for the evaluation of the NS1-detection devices and the
second for the evaluation of the antibody-detection kits. Each panel consisted of urine and saliva specimens
collected sequentially from 86 patients with a confirmed dengue infection. A total of 291 saliva and 440 urine
samples were included in the NS1-evaluation panel and 530 saliva and 528 urine specimens constituted the
antibody-evaluation panel. All samples were tested in parallel by in-house ELISAs and by the commercial RDTs.
Results: The RDTs demonstrated an overall sensitivity of 15.5 %/27.9 %/10.7 % for NS1/IgG/IgA detection in urine
samples and 20.4 %/ 34.8 %/11 %/6.2 % for NS1/IgG/IgM/IgA detection in saliva samples. Compared to the
in-house NS1 ELISA, the results obtained with the NS1 RDT demonstrated a good correlation with urine samples
(kappa coefficient: 0.88) but not with saliva specimens (kappa coefficient: 0.28). RDTs designed for antibody
detection in saliva and urine were extremely specific (100 %), but less sensitive than the in-house ELISAs (i.e.,
reduction of the overall sensitivity by 12.2 % for the RDT designed for IgG detection in urine and by 23.7 % for the
RDT detecting anti-DENV IgM in saliva). IgM were not detected in urine, either by RDT or ELISA.
Conclusions: Although the RDTs evaluated here offer an apparently attractive approach for dengue diagnosis, this
study suggests that these new commercial kits would require further improvement to increase the sensitivity.
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Background
Dengue is the most common arboviral disease world-
wide, with almost 130 countries of tropical or subtrop-
ical regions for which there is good evidence of dengue
occurrence [1]. Dengue illness begins with undifferenti-
ated symptoms, common to several other infectious
diseases such as malaria, influenza or other arboviral
diseases. After a few days, most patients begin to recover
but some progress to severe hemorrhagic disease forms
that can result in death without proper medical care.
Early clinical management based on accurate rehydra-
tion can prevent life-threatening complications [2].
Hence, the need for an early diagnosis of dengue
infection.
Direct diagnosis of dengue is based on dengue virus
(DENV) isolation, or detection of the viral genome or
NS1 antigen. Indirect diagnosis using serological
methods to detect anti-DENV IgM and IgG is com-
monly employed. Anti-DENV IgA are also detectable
during a DENV infection but tests to detect this
immunoglobulin isotype are not often used in routine
diagnosis [3–5]. Rapid diagnostic tests (RDTs) for NS1
and anti-DENV antibody detection in blood have been
developed in order to help physicians make rapid and
informed decisions about adapted clinical management.
Until recently, only blood samples were used for dengue
diagnosis but it has been shown in several studies that
urine and saliva can also be employed [6–11].
Standard Diagnostics (SD; Kyonggi-do, South Korea)
has developed RDTs able to detect markers of dengue
infection in urine and saliva specimens. They designed a
NS1 RDT, a combined anti-DENV IgM/IgG RDT and an
anti-DENV IgA RDT adapted for testing both urine and
saliva clinical specimens. The aim of this study was to
evaluate the performances of these diagnostic tools. The
results obtained with the RDTs were compared with
those of in-house ELISAs.
Methods
Clinical samples
Two panels of clinical specimens were used: the first one
for the evaluation of the NS1 test and the second for the
antibody detection assays. Each panel consisted of urine,
saliva and plasma specimens collected sequentially from
86 patients with a confirmed dengue infection. A con-
firmed dengue case was defined by the detection of viral
RNA by RT-PCR and/or the detection of the NS1 pro-
tein and/or an IgM seroconversion and/or a fourfold
antibody titer increase measured by hemagglutination
inhibition assay (HIA) in paired plasma of patients
presenting with symptoms suggestive of a dengue infec-
tion. Fifty patients presented with mild symptoms
defined by the 1997 WHO criteria as classical dengue
fever (DF) and 36 patients experienced severe symptoms
compatible with the diagnostic of dengue hemorrhagic
fever (DHF) or dengue shock syndrome (DSS) [12]. The
immune status of 73 patients was determined by HIA:
24 patients experienced a primary infection whereas 49
had a secondary infection. The NS1 panel consisted of
samples collected during hospitalization (i.e., from day 1
to 12 after onset of fever), whereas samples collected
during a weekly follow-up until three months after
discharge were also included in the second panel
designed for the evaluation of the antibody-detection
RDTs. Four to ten urine and saliva specimens and two
to five plasma samples obtained from each patient were
included in these panels. A total of 241 plasma, 291
saliva and 440 urine samples were included in the NS1-
evaluation panel and 292 plasma, 530 saliva and 528
urine specimens constituted the antibody-evaluation
panel. The samples of the antibody panel were classified
into three categories based on whether the correspond-
ing plasma sample collected at the same time point was
weakly, averagely or highly positive in antibody based on
the optical density (OD) measured by ELISA. Similarly,
the samples included in the NS1 panel were classified
into weakly, averagely or highly positive based on the
concentration of NS1 measured by ELISA in the corre-
sponding plasma specimen. The NS1 quantification was
only performed for samples obtained from patients in-
fected by a virus from serotype 1 (DENV-1) as only
quantified recombinant NS1 protein from DENV-1 was
available in our laboratory. The three categories were de-
fined arbitrarily by calculating the 1st and 3rd quartile of
300 OD/concentration values of antibodies and NS1
protein obtained with 300 positive plasma samples.
Weakly, averagely and highly positive plasma samples
corresponded to samples with a result lower than the 1st
quartile, between the 1st and the 3rd quartile and greater
than the 3rd quartile, respectively. Twenty-five speci-
mens obtained from healthy controls recruited during a
community-based study were also added to the panels in
order to assess the specificity. These negative controls
were obtained from household members of some of the
patients identified during the hospital-based study and
who did not experience any symptoms and had no bio-
logical evidence of DENV infection (DENV RT-PCR
negative, NS1 RDT negative and absence of HI
antibody).
In-house ELISAs
The RDTs evaluated in this study were compared to in-
house ELISAs and we will refer to them as “Institut
Pasteur Cambodia (IPC) ELISAs” throughout the manu-
script. A capture ELISA was used to detect NS1 in
plasma, urine and saliva. Anti-DENV IgG were detected
in plasma, urine and saliva by an indirect ELISA whereas
anti-DENV IgM and IgA were detected by capture
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ELISAs (MAC-ELISA and AAC-ELISA, respectively).
These ELISAs and their performances were previously
described in detail by Andries et al. [11].
Rapid diagnostic tests
In this study, prototype immunochromatographic kits
developed by Standard Diagnostics for NS1 and anti-
DENV IgG, IgM and IgA detection were evaluated.
Anti-DENV IgG and IgM were detected by the same de-
vice, whereas NS1 and anti-DENV IgA were detected by
two other distinct devices. Each kit was either designed
for saliva or urine specimen analysis. The characteristics
of the six different devices are summarized in the
Additional file 1. All tests were strictly performed
according to the manufacturer’s instructions provided
with the kits.
Statistical analysis
Statistical analysis was performed using STATA version
11.0 (StataCorp, USA). Significance was assigned at P < 0.05
for all parameters and were two-sided. Uncertainty was
expressed by 95 % confidence intervals (CI95). Statistical
differences between various categorical groups were de-
tected using McNemar’s test. Agreement between IPC ELI-
SAs and RDTs was measured by agreement percentage and
kappa coefficient.
Results
DENV NS1 RDTs
A specificity of 100 % (25/25) was obtained for the NS1
RDT in urine, whereas the specificity of the saliva-based
RDT was 84 % (21/25).
The RDT and the IPC ELISA detected NS1 in 15.5 %
(68/440, CI95 = [12.2–19.2]) and 14.3 % (63/440, CI95
= [11.2–17.9]) of the urine samples, respectively. The
agreement between the two urine-based tests was 97.1 %
with a kappa coefficient of 0.88 (Additional file 2a). The
NS1 RDT and ELISA tested positive in 20.4 % (59/289,
CI95 = [16.2–25.9]) and 24.7 % (72/291, CI95 = [19.9–
30.1]) of the saliva specimens, respectively. An agree-
ment of 74.0 % was obtained between both tests with a
kappa coefficient of 0.28 (Additional file 2b). Two saliva
samples were excluded because an invalid result (no
control line) was obtained with the RDT. In total, 66 %
(159/241, CI95 = [59.6–71.9]) of the plasma samples col-
lected at the same time points from the same dengue-
confirmed patients as the urine and saliva specimens
tested positive by NS1 IPC ELISA.
The NS1 detection rate by ELISAs and RDTs was
systematically higher in urine and saliva samples ob-
tained from patients with high NS1 concentration in the
plasma specimens obtained at the same time points
(Table 1).
The sensitivity of urine- and saliva-based NS1 tests
was highest in samples collected 4–7 days after the onset
of fever (DAOF) from patients experiencing a primary
infection (Table 2). IPC ELISA and RDT demonstrated
both a maximal sensitivity for NS1 detection of 21.5 %
(17/79, CI95 = [13.1–32.2]) in the urine samples col-
lected during the 4 to 7 first days of the disease in pa-
tients experiencing a primary infection. A sensitivity of
46.7 % (28/60, CI95 = [33.7–60]) was observed with the
saliva-based IPC ELISA whereas the RDT’s sensitivity
only reached a maximum of 33.9 % (20/59). In compari-
son, 93.9 % (31/33, CI95 = [79.8–99.3]) of the plasma
collected at DAOF 4–7 from the same patients experien-
cing a primary infection tested positive for NS1.
Anti-DENV antibody RDTs
All 25 urine and 25 saliva samples obtained from the
healthy controls tested negative for IgG, IgM and IgA by
RDTs.
Anti-DENV IgG were detected in 27.9 % (145/520,
CI95 = [24.1–32]) and 40.4 % (210/520, CI95 = [36.1–
44.7]) of the urine samples by RDT and IPC ELISA, re-
spectively. An agreement of 86.7 % was obtained
between the two assays and the kappa coefficient was
0.71 (Additional file 2c).
A total of 10.7 % (56/522, CI95 = [8.2–13.7]) and
27.2 % (142/522, CI95 = [23.4–31.2]) of the urine
samples tested positive by RDT and IPC ELISA for anti-
DENV IgA detection. Results were concordant for
81.2 % of the urine specimens with a kappa coefficient
of 0.42 (Additional file 2d).
The sensitivity of IgG and IgA antibody detection in
urine by the ELISAs was significantly higher than the
Table 1 Detection rate of NS1 in urine and saliva samples
Urine Saliva
IPC NS1 capture ELISA NS1 RDT IPC NS1 capture ELISA NS1 RDT
Weakly positive plasma 10.3 % (3/29) 10.3 % (3/29) 13.3 % (2/15) 20 % (3/15)
Averagely positive plasma 16.7 % (9/54) 16.7 % (9/54) 48.5 % (16/33) 18.2 % (6/33)
Highly positive plasma 50 % (17/34) 50 % (17/34) 64.7 % (11/17) 47.1 % (8/17)
p-value a <0.001 <0.001 0.011 0.094
The detection rates of NS1 in urine and saliva samples are presented according to the NS1 level in the corresponding plasma samples
a Comparison of NS1 positive rate in urine or saliva from patients whose corresponding plasma tested weakly, averagely or highly positive by NS1 ELISA
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sensitivity of the RDTs (McNemar p-value ≤0.001 for
IgG and IgA).
Anti-DENV IgM were not detected in urine speci-
mens, either by RDT or by IPC ELISA.
The overall detection rates of anti-DENV IgG, IgM
and IgA in saliva samples were respectively 34.8 % (181/
520, CI95 = [30.7–39.1]), 11 % (57/520, CI95 = [8.4–14])
and 6.2 % (32/520, CI95 = [4.2–8.6]) with the RDTs, and
51.5 % (268/520, CI95 = [47.1–55.9]), 34.8 % (181/520,
CI95 = [30.7–39.1]) and 22.7 % (118/520, CI95 = [19.2–
26.5]) with IPC ELISAs. Percentages of agreement be-
tween RDTs and IPC ELISAs for IgG, IgM and IgA de-
tection in saliva were 81 %, 75.8 and 82.3 %, respectively.
The corresponding kappa coefficients were 0.62, 0.36
and 0.32 (Additional file 2e, f and g). Saliva-based ELI-
SAs were significantly more sensitive than saliva-based
RDTs (McNemar p-value ≤0.001 for all antibodies).
In comparison, IPC ELISAs for IgG, IgM and IgA
detection in the plasma specimens obtained at the same
time point from the same patients demonstrated sensitiv-
ities of 53.3 % (152/285, CI95 = [47.4–59.2]), 34.6 % (97/
280, CI95 = [29.1–40.5]) and 40.1 % (116/289, CI95
= [34.4–46]), respectively. The antibody detection rates ob-
tained in plasma samples by IPC ELISAs were significantly
higher than those obtained in saliva and urine specimens
by RDTs and IPC ELISAs (McNemar p-value ≤0.001 for all
parameters).
For each of the three different antibody isotypes, there
was a direct relationship between the level of antibodies
in the plasma samples and the percentage of positive
urine and saliva samples tested by IPC ELISAs and RDTs
(Table 3). The higher the level of antibodies was in the
plasma sample, the higher the probability was for the
corresponding urine or saliva specimen to test positive.
The IgG saliva-based tests performed better with sam-
ples collected between DAOF 8–43. The RDT reached a
maximum sensitivity of approximately 60 % (61.5 % at
DAOF 8–14; 59.6 % at DAOF 15–28; 57.1 % at DAOF
29–43) and the IPC ELISA a sensitivity of 78 % (79.5 %
at DAOF 8–14; 78.9 % at DAOF 15–28; 75.7 % at DAOF
29–43) (Table 4). A total of 85 % of the plasma samples
collected between DAOF 8–43 tested positive. Three
months after the onset of fever, the sensitivity dropped
to 55.9 % with the saliva-based ELISA and 8.8 % with
the saliva-based RDT, whereas IgG were detected in
66.7 % of the corresponding plasma specimens (Table 4).
The sensitivity of the IPC and RDT IgG urine-based
tests peaked at DAOF 8–14 (ELISA: 71.8 %, RDT:
Table 2 Sensitivity of the different diagnostic tools for NS1 detection in plasma, urine and saliva
Total Primary infection Secondary infection
Plasma ELISA All samples 66 % (159/241) 95.7 % (66/69) 51.1 % (69/135)
DAOF≤ 3 94.4 % (67/71) 100 % (29/29) 88.6 % (31/35)
DAOF 4–7 66.7 % (82/123) 93.9 % (31/33) 51.4 % (36/70)
DAOF 8–12 21.3 % (10/47) 85.7 % (6/7) 6.7 % (2/30)
Urine ELISA All samples 14.3 % (63/440) 18.3 % (23/126) 8.1 % (20/246)
DAOF≤ 3 9.9 % (8/81) 15.6 % (5/32) 2.4 % (1/41)
DAOF 4–7 19.2 % (52/271) 21.5 % (17/79) 12.3 % (19/154)
DAOF 8–12 3.4 % (3/88) 6.7 % (1/15) 0 % (0/51)
Urine RDT All samples 15.5 % (68/440) 18.3 % (23/126) 10.6 % (26/246)
DAOF≤ 3 11.1 % (9/81) 15.6 % (5/32) 4.9 % (2/41)
DAOF 4–7 21 % (57/271) 21.5 % (17/79) 15.6 % (24/154)
DAOF 8–12 2.3 % (2/88) 6.7 % (1/15) 0 % (0/51)
Saliva ELISA All samples 24.7 % (72/291) 43.5 % (37/85) 15.5 % (27/174)
DAOF≤ 3 25.5 % (12/47) 41.2 % (7/17) 19.2 % (5/26)
DAOF 4–7 29.9 % (55/184) 46.7 % (28/60) 19.4 % (21/108)
DAOF 8–12 8.3 % (5/60) 25 % (2/8) 2.5 % (1/40)
Saliva RDT All samples 20.8 % (60/289) b 31 % (26/84) a 16.2 % (28/173) a
DAOF≤ 3 14.9 % (7/47) 23.5 % (4/17) 11.5 % (3/26)
DAOF 4–7 25.7 % (47/183) a 33.9 % (20/59) a 19.4 % (21/108) a
DAOF 8–12 10.2 % (6/59) a 25 % (2/8) 10.3 % (4/39) a
The sensitivity of the different diagnostic tools for NS1 detection in plasma, urine and saliva of DENV-infected patients is presented according to the time of
sampling after the onset of the fever and the immune status of the patients
DAOF Day After Onset of Fever
a One invalid result
b Two invalid results
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62.8 %). Then, the sensitivity of the ELISA and the rapid
test decreased gradually. At DAOF 90–103, only 12.1
and 3 % of the urine samples still tested positive by
ELISA and RDT, respectively (Table 4).
The second week after the beginning of the disease
was the optimal time to detect IgM in both saliva and
plasma samples. The IgM detection rates in saliva sam-
ples by ELISA and RDT reached a maximum of 69.2 and
24.4 %, respectively, whereas 81 % of the corresponding
plasma samples tested positive by MAC-ELISA
(Table 4).
All IgA tests demonstrated a maximal sensitivity at
DAOF 8–14 (saliva: 64.4 % with ELISA and 17.1 % with
RDT; urine: 67.1 % with ELISA and 31.6 % with RDT;
plasma ELISA: 90.5 %). No positive results were ob-
tained with RDTs at DAOF 29–43 whereas 5.4 % of the
Table 3 Detection rate of antibodies in urine and saliva samples
Urine Saliva
IPC ELISA RDT IPC ELISA RDT
IgG Weakly positive plasma 48.1 % (13/27) 29.6 % (8/27) 48.1 % (13/27) 29.6 % (8/27)
Averagely positive plasma 50 % (41/82) 36.6 % (30/82) 74.4 % (61/82) 48.8 % (40/82)
Highly positive plasma 72.1 % (31/43) 62.8 % (27/43) 93 % (40/43) 67.4 % (29/43)
p-value a 0.041 0.006 <0.001 0.008
IgM Weakly positive plasma 0 % (0/25) 0 % (0/25) 40 % (10/25) 8 % (2/25)
Averagely positive plasma 0 % (0/54) 0 % (0/54) 83.3 % (45/54) 22.2 % (12/54)
Highly positive plasma 0 % (0/18) 0 % (0/18) 100 % (18/18) 44.4 % (8/18)
p-value a 1 1 <0.001 0.019
IgA Weakly positive plasma 18.2 % (6/33) 0 % (0/33) 12.1 % (4/33) 0 % (0/33)
Averagely positive plasma 50 % (31/62) 27.4 % (17/62) 62.3 % (38/61) b 13.1 % (8/61) b
Highly positive plasma 100 % (21/21) 71.4 % (15/21) 81 % (17/21) 23.8 % (5/21)
p-value a <0.001 <0.001 <0.001 0.021
The detection rates of antibodies in urine and saliva samples are presented according to the level of the immunoglobulin in the corresponding plasma samples
a Comparison of antibodies positive rate in urine or saliva from patients whose corresponding plasma tested weakly, averagely or highly positive for the
same biomarker
b One invalid result
Table 4 Sensitivity of the different diagnostic tools for IgG, IgM and IgA detection
DAOF (Day after onset of fever)
1–3 4–7 8–14 15–28 29–43 90–103 Total
Plasma ELISA IgG 3.8 % (2/53) 48.2 % (54/112) 85.7 % (36/42) NA 84.4 % (38/45) 66.7 % (22/33) 53.3 % (152/285)
IgM 3.9 % (2/51) 49.1 % (55/112) 81 % (34/42) NA 13.6 % (6/44) 0 % (0/31) 34.6 % (97/280)
IgG or IgM 8.2 % (4/49) 64 % (71/111) 100 % (42/42) NA 82.9 % (34/41) 78.6 % (22/28) 63.8 % (173/271)
IgA 3.8 % (2/53) 47 % (54/115) 90.5 % (38/42) NA 40.4 % (19/47) 9.4 % (3/32) 40.1 % (116/289)
Saliva ELISA IgG 5.4 % (3/56) 38.2 % (86/225) 79.5 % (62/78) 78.9 % (45/57) 75.7 % (53/70) 55.9 % (19/34) 51.5 % (268/520)
IgM 3.6 % (2/56) 44.4 % (100/225) 69.2 % (54/78) 35.1 % (20/57) 7.1 % (5/70) 0 % (0/34) 34.8 % (181/520)
IgG or IgM 8.9 % (5/56) 56.9 % (128/225) 92.3 % (72/78) 94.7 % (54/57) 77.1 % (54/70) 55.9 % (19/34) 63.8 % (332/520)
IgA 0 % (0/57) 24.8 % (55/222) 64.4 % (49/76) 18.2 % (10/55) 5.4 % (4/74) 0 % (0/36) 22.7 % (118/520)
Saliva RDT IgG 0 % (0/56) 24.9 % (56/225) 61.5 % (48/78) 59.6 % (34/57) 57.1 % (40/70) 8.8 % (3/34) 34.8 % (181/520)
IgM 0 % (0/56) 15.6 % (35/225) 24.4 % (19/78) 3.5 % (2/57) 1.4 % (1/70) 0 % (0/34) 11 % (57/520)
IgG or IgM 0 % (0/56) 32 % (72/225) 70.5 % (55/78) 61.4 % (35/57) 57.1 % (40/70) 8.8 % (3/34) 39.4 % (205/520)
IgA 1.8 % (1/57) 8.1 % (18/222) 17.1 % (13/76) 0 % (0/55) 0 % (0/74) 0 % (0/36) 6.2 % (32/520)
Urine ELISA IgG 3.3 % (2/61) 41.3 % (93/225) 71.8 % (56/78) 58.5 % (31/53) 34.3 % (24/70) 12.1 % (4/33) 40.4 % (210/520)
IgA 0 % (0/61) 25.7 % (58/226) 67.1 % (53/79) 50.9 % (27/53) 5.7 % (4/70) 0 % (0/33) 27.2 % (142/522)
Urine RDT IgG 0 % (0/61) 25.8 % (58/225) 62.8 % (49/78) 45.3 % (24/53) 18.6 % (13/70) 3 % (1/33) 27.9 % (145/520)
IgA 0 % (0/61) 11.5 % (26/226) 31.6 % (25/79) 9.4 % (5/53) 0 % (0/70) 0 % (0/33) 10.7 % (56/522)
The sensitivity of the different diagnostic tools for IgG, IgM and IgA detection in plasma, urine and saliva is presented according to the time of sampling after the
onset of fever
DAOF Day After the Onset of Fever, NA no sample available
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saliva, 5.7 % of the urine and 40.4 % of the plasma sam-
ples tested positive by IPC ELISA. Three months after
the onset of fever, anti-DENV IgA were not detected by
saliva- and urine-based tests but 9.4 % of the plasma
samples still tested positive (Table 4).
Regardless of the diagnostic test, ELISA or RDT, and
the biological fluid tested, the detection rates of anti-
DENV IgG and IgA isotypes were higher in samples
collected from patients experiencing a secondary infec-
tion (Table 5). With IPC and RDT tests designed for
IgM detection in saliva and in plasma, no significant
differences were observed between primary and second-
ary infections (Table 5).
The antibody RDT was designed to concomitantly de-
tect anti-DENV IgM and IgG. The combination of IgM
and IgG results allowed an increase of the overall diag-
nostic sensitivity in saliva from 34.8 % with the IgG re-
sults alone to 39.4 % when both IgG and IgM were
tested. This improvement in sensitivity was best for sam-
ples collected at DAOF 8–14 (9 % increase) and DAOF
4–7 (7.1 % increase). In comparison, 63.8 % of the
plasma samples tested positive for dengue when IPC
MAC-ELISA and IPC IgG indirect ELISA results were
combined (Table 4).
Discussion
The epidemiology of dengue is very dynamic both in
terms of geographical spread and intensity. Transmission
is emerging or reemerging in areas where the disease
was absent and it is also intensifying in some regions
where dengue was already endemic, with both an in-
crease in the number of cases and an increase in severity
of the disease [13]. This dramatic increase in the global
burden of dengue has lead to the willingness to develop
easy tools for the disease diagnosis, to help in the early
detection of new epidemics and assist physicians to pro-
vide accurate treatment and management of patients as
early as possible. The ability to rapidly confirm acute
dengue infection for patients presenting to a clinical set-
ting could also avoid the unnecessary use of antibiotics
and other drugs.
Saliva and urine specimens provide interesting
advances for dengue diagnosis as their collection is non-
invasive and thus well accepted by patients. In addition,
it does not require medically-trained staff and the sam-
ples are easy to process as it does not require on-site
laboratory for centrifugation. In a previous study, we
demonstrated that urine and saliva samples were inter-
esting alternatives to venous blood specimens for dengue
diagnosis in all situations when blood collection was
difficult [11]. In this recent study, in-house ELISAs for
NS1 antigen and anti-DENV antibodies detection were
developed to assess the value of urine and saliva speci-
mens for dengue diagnosis. We showed that antibody
detection in saliva and urine was useful for instances
such as outbreak investigations or in young children, in
addition to the all situations when blood could not be
easily collected (e.g., lack of phlebotomist, refusal of pro-
cedure, etc.). Good salivary- and urinary-based RDTs
could be valuable tools for dengue diagnosis as they
combine easy sampling methods with rapid, equipment-
free testing. Such kits could be used by nurses, at the pa-
tient’s bedside, in hospital settings but also by general
practitioners in private clinics or by epidemiologists dur-
ing outbreak investigations and field studies.
Some oral fluid RDTs have already been marketed for
viral infection diagnosis. One immunochromatographic
assay designed for anti-hepatitis C virus (HCV) antibody
detection in saliva and at least two anti-human immuno-
deficiency virus (HIV) antibody detection kits have been
commercialized. The anti-HCV antibodies device
showed very good performances [14, 15] and seemed to
be an interesting tool for field work with people at risk
of HCV infection [16, 17]. The anti-HIV antibody oral
fluid devices also demonstrated good performances but
slightly lower than RDTs used for antibody detection in
Table 5 Sensitivity of the different tools for IgG, IgM and IgA detection
Plasma Saliva Urine
IPC ELISA IPC ELISA RDT IPC ELISA RDT
IgG Primary 16.1 % (13/81) 13.2 % (19/144) 8.3 % (12/144) 5.6 % (8/143) 1.4 % (2/143)
Secondary 72.9 % (124/170) 68 % (208/306) 48 % (147/306) 56.8 % (171/301) 39.2 % (118/301)
p-value a <0.001 <0.001 <0.001 <0.001 <0.001
IgM Primary 31.2 % (24/77) 33.3 % (48/144) 11.1 % (16/144) 0 % (0/143) 0 % (0/143)
Secondary 37.1 % (62/167) 34 % (104/306) 7.5 % (23/306) 0 % (0/301) 0 % (0/301)
p-value a 0.365 0.891 0.206 1 1
IgA Primary 12.7 % (10/79) 2.9 % (4/140) 2.1 % (3/140) 4.2 % (6/143) 4.2 % (6/143)
Secondary 53.2 % (91/171) 30.5 % (92/302) 6.6 % (20/302) 38.5 % (116/301) 14.3 % (43/301)
p-value a <0.001 <0.001 0.049 <0.001 0.002
The sensitivity of the different tools for IgG, IgM and IgA detection in plasma, urine and saliva is presented according to the patients’ immune status
a Comparison of sensitivity between primary and secondary infection
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blood [18–20]. There is currently no rapid test designed
for the diagnosis of viral infection in urine but good
RDTs have been developed for bacterial antigen detec-
tion in urine, e.g., for Legionella pneumophila serogroup
1 and Streptococcus pneumoniae [21–23]. A rapid immu-
nochromatographic test for Plasmodium falciparum
HRP2 antigen detection in urine is currently in clinical
development and a preliminary evaluation reported a
sensitivity of 83.8 % compared to blood smear micros-
copy, with a lower sensitivity in urine from patients with
a low parasitemia [24].
This study was the first evaluation of rapid diagnostic
tests designed by the Standard Diagnostics company to
detect NS1 antigen and anti-DENV IgG, IgM and IgA in
urine and saliva specimens. The present study demon-
strates differing performances of these kits in compari-
son to the in-house ELISAs that we previously
developed. The RDT designed for the detection of NS1
in saliva lacked sensitivity and specificity compared to
the in-house ELISA, resulting in a very low kappa coeffi-
cient (0.28). The results obtained by the NS1 RDT with
urine specimens were close to those observed with our
ELISA with sensitivities of 15.5 and 14.3 %, respectively,
and a kappa coefficient of 0.88. The slightly better per-
formance observed with the RDT in comparison to the
ELISA can be explained by a reduced sensitivity of the
IPC in-house ELISA for the detection of NS1 protein
from serotype 2 dengue viruses. Indeed all of the nine
urine samples that tested positive with the RDT but
negative with IPC ELISA (Additional file 2a) were ob-
tained from patients infected by DENV-2. The reduced
specificity observed with the RDT in saliva specimens
could be a consequence of a non-specific adhesion of
the detector colloidal particles, which are referred to as
conjugates, to the nitrocellulose membrane. This
phenomenon has been described with saliva but not with
other body fluids. Indeed, mucin and other protein-
aceous and viscous substances present in high concen-
tration in saliva are believed to adhere to the membrane
and aggregate with the conjugates causing non-specific
reaction [25].
The IgG RDT demonstrated a good agreement, defined
by a kappa coefficient ≥ 0.61 [26], with the in-house IgG
indirect ELISAs, in both saliva (kappa coefficient: 0.62)
and urine (kappa coefficient: 0.71) specimens. IgM and
IgA RDTs performed less well in both saliva and urine.
The agreement of these tests with the corresponding IPC
ELISAs was only fair (0.21 ≤ kappa coefficient < 0.41) to
moderate (0.41 ≤ kappa coefficient < 0.61). Sensitivities of
the RDT for IgM and IgA detection in saliva were lower
than 50 % even in patients with high levels of the corre-
sponding antibody isotype in the plasma specimens col-
lected at the same time-points. IgM levels peak in the
serum about two weeks after the onset of symptoms and
then decline generally to undetectable levels over 2–3
months. Anti-dengue serum IgG is generally detectable at
low titres at the end of the first week of illness, increasing
slowly thereafter, with serum IgG still detectable after sev-
eral months, and probably even for life. During a second-
ary dengue infection IgG is detectable at high levels, even
in the acute phase, and persists for periods lasting from
10 months to life. Early convalescent stage IgM levels are
significantly lower in secondary infections than in primary
ones and may be undetectable in some cases, depending
on the test used. Combining IgM and IgG test therefore
offers the possibility to serologically detect a dengue infec-
tion during a larger window of time as well as during
some secondary infections when IgM are not detectable.
In addition, the comparison of IgM and IgG results distin-
guishes primary and secondary dengue infections [2]. As a
result, diagnostic kits combining both anti-dengue IgM
and IgG antibodies became increasingly popular. As previ-
ously described by Vasquez et al., anti-DENV IgM were
not found in urine, either by in-house ELISA or by RDT
[7]. The combination of IgG and IgM detection in the
same device was thus not useful to test urine samples. In
saliva specimens, the combination of IgM and IgG tests in
the same device provided a slight improvement of the
overall diagnostic sensitivity compared to the sensitivities
of IgG and IgM tests taken separately (39.8 % for the com-
bination, 35.2 % for IgG alone and 10.8 % for IgM tested
separately). Urine and saliva are biological fluids that con-
tain very low levels of antibodies compared to blood [27,
28]. It was estimated that the IgA, IgG and IgM levels in
saliva specimens were approximately 1/10, 1/800 and 1/
400 of those measured in serum [27]. RDTs designed by
SD company only required 5 μl of saliva and 10 μl of
urine. These volumes ensure correct performances of the
kits for the detection of anti-DENV antibodies in blood
[29, 30] but could be sub-optimal for the detection of anti-
bodies present in lower concentrations in other body
fluids. Indeed, Zhang et al. developed a rapid test for the
detection of anti-DENV IgG in saliva but this assay re-
quired a volume of 100 μl [25].
The high viscosity of some saliva specimens was a
interfering with the migration of the sample on the strip
test. Invalid results with RDTs were obtained because of
the non-appearance of the control line. The use of a di-
lution buffer enabling to reduce the saliva viscosity could
eventually prevent these migration issues as even a
freeze–thaw cycle that in theory should break down the
mucopolysaccharides responsible of the viscosity did not
provide any improvement.
This study has several limitations. Saliva and urine
samples were frozen for several months at −80 °C before
the evaluation and it is not known if this process could
have altered the stability of the NS1 antigen or the anti-
bodies. Additionally, the performances of these diagnostic
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kits were not evaluated for all four dengue virus serotypes
as this study was conducted using well-characterized and
sequential clinical samples prospectively collected during
a DENV-1 epidemic, when the DENV-2 and DENV-4
were circulating at lower level and no DENV-3 was de-
tected. Specificity results should also be interpreted with
caution as they were generated from a limited number of
available negative controls. Moreover we used only sam-
ples from febrile, non-dengue patients to evaluate the spe-
cificity. Non-specific binding with the saliva RDTs might
have been more pronounced in these samples than it
would have been with samples from healthy individuals.
Conclusions
Although urine and oral fluid-based rapid diagnostic
tests offer an attractive apparent alternative option to
blood for dengue diagnosis, this evaluation suggests
that this first series of diagnostic tools developed by a
commercial company really need further improvement
especially in a context where the body fluids explored
are already known to perform less well compared to
blood specimens for the diagnosis of dengue [11]. As
for any other diagnostic test evaluation, additional in-
dependent study would be beneficial in order to pro-
vide a better overview of the performances of these
kits in different settings and epidemic situations.
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